Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;42(1):81-90.
doi: 10.1016/j.ccm.2020.11.014. Epub 2021 Jan 12.

Chronic Thromboembolic Disease and Chronic Thromboembolic Pulmonary Hypertension

Irene M Lang  1 , Ioana A Campean  2 , Roela Sadushi-Kolici  2 , Roza Badr-Eslam  2 , Christian Gerges  2 , Nika Skoro-Sajer  2
Affiliations
Free article
Review

Chronic Thromboembolic Disease and Chronic Thromboembolic Pulmonary Hypertension

Irene M Lang et al. Clin Chest Med. 2021 Mar.
Free article

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) and chronic thromboembolic pulmonary vascular disease (CTED) are rare manifestations of venous thromboembolism. Presumably, CTEPH and CTED are variants of the same pathophysiological mechanism. CTEPH and CTED can be near-cured by pulmonary endarterectomy, balloon pulmonary angioplasty, and medical treatment with Riociguat or subcutaneous treprostinil, which are the approved drugs.

Keywords: Acute pulmonary embolism; Chronic thromboembolic pulmonary hypertension; Chronic thromboembolic pulmonary vascular disease; Venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Disclosures I.M. Lang has relationships with drug companies including AOPOrphan Pharmaceuticals AG, Actelion-Janssen, MSD, United Therapeutics, Medtronic, and Ferrer. In addition to being investigator in trials involving these companies, relationships include consultancy service, research grants, and membership of scientific advisory boards. I.A. Campean has nothing to disclose. R. Sadushi-Kolici has relationships with drug companies including Actelion, AOP Orphan Pharmaceuticals, Bayer-Schering, GlaxoSmithKline, and SciPharm Sàrl. In addition, Roela Sadushi-Kolici is an investigator in trials involving these companies, relationships include consultancy service, and research grants. R. Badr-Eslam has received compensation for scientific symposia from Actelion-Janssen, AOPOrphan Pharmaceuticals, AstraZeneca, and GlaxoSmithKline. C. Gerges has received compensation for scientific symposia from Actelion-Janssen, AOPOrphan Pharmaceuticals, AstraZeneca, and GlaxoSmithKline. N. Skoro-Sajer has relationships with drug companies, including Actelion, AOP Orphan Pharmaceuticals, Bayer AG, GlaxoSmithKline, Pfizer, and United Therapeutics. In addition, Nika Skoro-Sajer is an investigator in trials involving these companies, relationships include consultancy service, and research grants.

Publication types

MeSH terms